Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Boston Scientific and Guidant Announce Merger

By HospiMedica staff writers
Posted on 27 Jan 2006
Following a dizzying round of bids from two companies since early December, Guidant Corp. More...
(Indianapolis, IN, USA) has announced that its board has approved and entered into a merger agreement with Boston Scientific (Natick, MA, USA), which will acquire Guidant for cash and stock worth U.S.$80 per share, or about $27 billion.

Only days earlier, Guidant announced a deal with Johnson & Johnson (J&J, New Brunswick, NJ, USA; www.jnj.com), which offered Guidant $71 per share, or about $24.2 billion. However, Boston Scientific has continued to increase its own offer for Guidant, which reached $73 per share in mid-January. After Boston Scientific heard about the Guidant/J&J deal, the company increased its offer to $80 per share.

Guidant and Boston Scientific believe their combined company should be attractive to shareholders. It will have leading positions in growth markets, notably cardiovascular devices, and have total revenues in 2006 of nearly $9 billion. "Guidant and Boston Scientific share an entrepreneurial spirit, highly talented employees, strong customer relationships, and an ability to pioneer lifesaving therapies for patients around the world,” observed Pete Nicholas, chairman of Boston Scientific.

When J&J began its courtship of Guidant, the company hoped to gain a foothold in the heart-defibrillator business, which is growing about 20% per year. J&J's initial offer of $24.5 billion was made in December 2004, but following malfunction problems at Guidant, it reduced its offer to $21.5 billion. Then Boston Scientific came into the game.

Boston Scientific has also entered into an agreement with Abbott Laboratories (Abbott Park, IL, USA), under which Boston will divest the vascular intervention and endovascular businesses of Guidant, while agreeing to share rights to Guidant's drug-eluting stent program. Boston will receive $4.1 billion from Abbott for the Guidant assets, a loan of $900 million, and Abbott's agreement to acquire $1.4 billion of Boston's common stock. This move is designed to help secure antitrust approvals for the Boston/Guidant transaction.






Related Links:
Boston Scientific
J&J
Guidant

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.